摘要
5型磷酸二酯酶抑制剂使用方便、高效、不良反应小,是治疗勃起功能障碍的一线药物。西地那非自1998年面世以来,是目前研究最透彻的5型磷酸二酯酶抑制剂。临床试验主要针对不同患者群体,包括合并有心血管疾病、糖尿病、抑郁症、前列腺根治术后和透析治疗等特殊人群,进行疗效和安全性研究。不良反应多为轻中度,主要表现为头痛、面部潮红、消化不良和短暂的视觉障碍。本文就5型磷酸二酯酶抑制剂治疗勃起功能障碍的疗效和安全性作一综述。
Phospodiesterase 5 inhibitors are recommended as first-line treatment of erectile dysfunction in many guidelines, because of their convenience, higher efficacy, and less side-effects. Since its first launch in 1998, sildenafil has been currently the best investigated phospodiesterase 5 inhibitor with respect to long-term trails and quantity. Clinical trials showed the efficacy of sildenafil compared with placebo in many of the groups of patients who have ED, including those with cardiovascular disease, diabetes mellitus, depression, radical prostatectomy and dialysis. Typically the adverse effects reported in patients from clinical trials of sildenafil have been mild to moderate, and commonly include flushing and dyspepsia and transient visual disturbances. This article summarized recent reports on efficacy and safety of phospodiese 5 inhibitors in the treatment of erectile dysfunction.
出处
《中华男科学杂志》
CAS
CSCD
2005年第8期631-634,共4页
National Journal of Andrology